- Home
- VRCA vs ANL Comparison
VRCA vs ANL Comparison
Compare VRCA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VRCA | ANL |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 52.0M |
| IPO Year | 2018 | 2023 |
Fundamental Metrics
Financial Performance| Metric | VRCA | ANL |
|---|---|---|
| Price | $8.06 | $1.10 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 359.1K | 10.1K |
| Earning Date | 11-14-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,829,000.00 | N/A |
| Revenue This Year | $332.45 | N/A |
| Revenue Next Year | $12.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 234.73 | N/A |
| 52 Week Low | $3.28 | $1.10 |
| 52 Week High | $12.50 | $2.99 |
Technical Indicators
Market Signals| Indicator | VRCA | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 68.08 | 26.54 |
| Support Level | $6.26 | $1.32 |
| Resistance Level | $9.82 | $1.59 |
| Average True Range (ATR) | 0.94 | 0.15 |
| MACD | 0.38 | -0.03 |
| Stochastic Oscillator | 73.36 | 16.95 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.